Goldman Sachs’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Goldman Sachs’s Portfolio CYT Stock Details CYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-11,670	Closed	-$22K	–	6352
2022 Q3	$22K	Sell	11,670 -12,769	-52%	-$33.3K	﹤0.01%	5920
2022 Q2	$73K	Buy	24,439 +10,642	+77%	+$27.2K	﹤0.01%	5948
2022 Q1	$52K	Buy	13,797 +1,660	+14%	+$9.45K	﹤0.01%	6267
2021 Q4	$138K	Buy	+12,137	New	+$185K	﹤0.01%	6032
2021 Q3	–	Sell	-62,069	Closed	-$1.33M	–	6591
2021 Q2	$1.33M	Buy	+62,069	New	+$1.16M	﹤0.01%	4546

Other funds holding CYT

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

OMC

OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs's CYT Position: Q4 2022 in Review

Goldman Sachs sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q4 2022, closing a stake of 11,670 shares — an estimated $22K sold.

Goldman Sachs first reported a position in CYT in Q2 2021 and held it in 5 quarters. The position peaked at $1.33M in Q2 2021. 30 funds tracked by Wall St. Rank hold CYT as of Q4 2022.

Goldman Sachs reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Goldman Sachs sold 11,670 Cyteir Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $22K.
Goldman Sachs first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q2 2021 and held it in 5 quarters.
Goldman Sachs's Cyteir Therapeutics, Inc. Common Stock position peaked at $1.33M in Q2 2021.
30 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Goldman Sachs's 13F filing for Q4 2022, filed 13 Feb 2023.